Last update 01 Nov 2024

PT-112

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
(1R,2R)-1,2-cyclohexane-diaminepyrophosphato-platinum(II), Imifoplatin, Phosphaplatin PT-112
Target
Mechanism
DNA inhibitors(DNA inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
RegulationSpecial Review Project (CN), Orphan Drug (US)
Login to view timeline

Structure

Molecular FormulaC6H14N2Na2O7P2Pt
InChIKeyJTEYQLFSZYNTNY-DDCZJXQTSA-J
CAS Registry1109292-06-9

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Thymic Epithelial TumorPhase 2
US
06 Apr 2022
Hepatocellular CarcinomaPhase 2
CN
07 Mar 2018
Hepatocellular CarcinomaPhase 2
CN
07 Mar 2018
Hepatocellular CarcinomaPhase 2
CN
07 Mar 2018
Advanced Malignant Solid NeoplasmPhase 2
US
01 Jul 2014
Advanced Malignant Solid NeoplasmPhase 2
FR
01 Jul 2014
Metastatic castration-resistant prostate cancerPhase 2
US
01 Jul 2014
Metastatic castration-resistant prostate cancerPhase 2
FR
01 Jul 2014
Multiple MyelomaPreclinical-07 Feb 2018
Non-Small Cell Lung CancerPreclinical
TW
01 Aug 2016
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
11
(dwhvqyvlkl) = oroxqfnobu zifkfmqzsg (efivivrnov )
Positive
05 Oct 2023
Phase 2
10
(jisnhyzwdx) = njytryadqf kmilksjssy (nmlgomjxzm )
Positive
26 May 2023
Phase 2
18
(arvihbyyng) = Common treatment-related adverse events (TRAEs) were anemia (50%), fatigue (50%), thrombocytopenia (44%), nausea (44%) and anorexia (44%). nxcjaspqds (wmqxnoskro )
Positive
08 Dec 2022
Phase 2
66
(zruqxwrxlk) = javvzlbayk ghhugqbnat (glznluojnu )
Positive
27 May 2022
Phase 1
36
(vmjhschgre) = 28% prysvyzswb (vhueyvipln )
Positive
18 Sep 2020
Phase 1/2
68
(omhhiqecfj) = The most common PT-112 TRAEs were fatigue (40%, Gr ≤2) with mono-Tx; fatigue (39%, Gr ≤2) with PAVE. cdpnmmgqpy (hteknvoxye )
Positive
19 Feb 2020
Phase 1
62
bauyvyuaku(zqarxvpdzv) = no significant acute neurotoxicity was reported in 533 infusions rtaevmomql (tkmaunxopo )
Positive
22 Oct 2018
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free